These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1869100)

  • 21. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
    Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
    J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
    Bolis G; Favalli G; Danese S; Zanaboni F; Mangili G; Scarabelli C; Tateo S; Valsecchi MG; Scarfone G; Richiardi G; Frigerio L; Melpignano M; Villa A; Parazzini F
    J Clin Oncol; 1997 May; 15(5):1938-44. PubMed ID: 9164205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma.
    Erickson LD; Hartmann LC; Su JQ; Nielsen SN; Pfeifel DM; Goldberg RM; Levitt R; Stanhope CR
    Gynecol Oncol; 1994 Aug; 54(2):196-200. PubMed ID: 8063245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The feasibility of early administration of combination chemotherapy following cytoreductive surgery and second-look operation in patients with stage III ovarian carcinoma: a pilot study.
    Vardi JR; Rafla SD; Malhotra C; Tadros G; Charney T; Shebes M; Berkowitz BJ; Kehoe JE; Tancer LM
    Gynecol Oncol; 1989 Jul; 34(1):12-5. PubMed ID: 2737518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group.
    Lambert HE; Berry RJ
    Br Med J (Clin Res Ed); 1985 Mar; 290(6472):889-93. PubMed ID: 3919831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group Study.
    Alberts DS; Mason-Liddil N; O'Toole RV; Abbott TM; Kronmal R; Hilgers RD; Surwit EA; Eyre HJ; Baker LH
    Gynecol Oncol; 1989 Jan; 32(1):16-21. PubMed ID: 2642453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymoma. A retrospective study of 87 cases.
    Park HS; Shin DM; Lee JS; Komaki R; Pollack A; Putnam JB; Cox JD; Hong WK
    Cancer; 1994 May; 73(10):2491-8. PubMed ID: 8174044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma. Phase II.
    Vardi JR; Tadros GH; Zamurovic D; Rafla SD
    Acta Obstet Gynecol Scand; 1992 Jul; 71(5):361-7. PubMed ID: 1326212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
    Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
    Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look.
    Ojeda-González MB; Alvárez-López I; Alonso-Muñoz MC; Badía-Serra J; Delgado-Latre E; de Andrés-Basauri L; López-López JJ
    Oncology; 1991; 48(1):7-12. PubMed ID: 1987501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group.
    Williams SD; Blessing JA; Moore DH; Homesley HD; Adcock L
    Ann Intern Med; 1989 Jul; 111(1):22-7. PubMed ID: 2472080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Homesley HD; Creasman WT; Berman ML; Ball H; Berek JS; Woodward J
    J Clin Oncol; 1995 Jul; 13(7):1589-99. PubMed ID: 7602348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS; Green S; Hannigan EV; O'Toole R; Stock-Novack D; Anderson P; Surwit EA; Malvlya VK; Nahhas WA; Jolles CJ
    J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
    J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
    Omura GA; Brady MF; Homesley HD; Yordan E; Major FJ; Buchsbaum HJ; Park RC
    J Clin Oncol; 1991 Jul; 9(7):1138-50. PubMed ID: 1904477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.